Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Resuscitace při traumatu s nízkým titrem skupiny O plná krev nebo produkty (TROOP)

18. září 2026 aktualizováno: Jan O. Jansen, University of Alabama at Birmingham

The goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who require large-volume blood transfusions.

Přehled studie

Postavení

Dokončeno

Detailní popis

Trauma is one of the leading causes of death in the United States, and disproportionately affects the young, killing those who might otherwise have lived long and productive lives. Injuries account for more years of potential life lost before age 75 than any other cause. Hemorrhage remains the most common cause of preventable death after injury, and blood transfusion is an essential part of treatment. Modern blood banking practices separate donated whole blood into components. The current standard of care in trauma transfusion is the balanced administration of equal numbers of units of blood components (packed red blood cells, plasma, and platelets), effectively attempting to reconstitute whole blood. A renewed approach to blood transfusion therapy in trauma is to use whole blood from the outset, which has not been separated. Compared with component therapy, whole blood offers several potential advantages, but there are only a small number of, mostly observational, studies comparing whole blood and component therapy, and they are very heterogeneous.

The TROOP trial will include injured adults with hemorrhagic shock anticipated to require massive blood transfusions, who will be randomized to receive either whole blood (LTOWB) or blood components. This will allow a direct comparison to see if one type of transfusion is more strongly associated with improved clinical outcomes over the other.

The knowledge gained from this clinical trial will transform the way in which massively bleeding trauma patients are transfused. The trial is exceedingly well positioned to improve mortality from trauma and reduce the number of preventable deaths resulting from hemorrhagic shock.

Typ studie

Intervenční

Zápis (Aktuální)

1100

Fáze

  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

    • Alabama
      • Birmingham, Alabama, Spojené státy, 35294
        • University of Alabama at Birmingham, UAB Hospital
    • California
      • Los Angeles, California, Spojené státy, 90033
        • Los Angeles County + University of Southern California (LAC + USC) Medical Center
    • Louisiana
      • New Orleans, Louisiana, Spojené státy, 70112
        • University Medical Center New Orleans LCMC Health
    • Maryland
      • Baltimore, Maryland, Spojené státy, 21201
        • University of Maryland Medical Center
    • Missouri
      • St Louis, Missouri, Spojené státy, 63110
        • Washington University School of Medicine
    • North Carolina
      • Winston-Salem, North Carolina, Spojené státy, 27157
        • Atrium Health Wake Forest Baptist
    • Ohio
      • Cincinnati, Ohio, Spojené státy, 45267
        • University of Cincinnati Medical Center
    • Oregon
      • Portland, Oregon, Spojené státy, 97239
        • Oregon Health and Sciences University Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Spojené státy, 19104
        • Penn Presbyterian Medical Center
    • Texas
      • Houston, Texas, Spojené státy, 77030
        • University of Texas Health Science Center Houston
      • San Antonio, Texas, Spojené státy, 78229
        • University of Texas Health San Antonio and University Health System
    • Washington
      • Seattle, Washington, Spojené státy, 98104
        • Harborview Medical Center
    • Wisconsin
      • Milwaukee, Wisconsin, Spojené státy, 53226
        • Froedtert Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

15 let a starší (Dítě, Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

  1. Adult trauma patient (estimated age > 15 or weight > 50 kg, if age unknown)

  2. Patient taken to trauma center directly from scene

  3. Commencement of blood transfusion (PRBC, plasma or LTOWB), in pre-hospital or in-hospital setting

  4. Activation of site-specific Massive Hemorrhage Protocol or Massive Transfusion Protocol

  5. Traumatic injury with at least one of the following:

    1. Confirmed or suspected acute major bleeding
    2. Assessment of Blood Consumption (ABC) Score ≥2

Exclusion Criteria:

  1. Patients who have received, prehospital or in-hospital more than two units of LTOWB; the equivalent in components (two units of packed red blood cells and two units of plasma); or a combination of the two (more than one unit of LTOWB, one unit of packed cells, and one unit of plasma). Most trauma centers hold two units of either packed red blood cells (with two units of plasma) or two units of LTOWB in the emergency department. This stock is used to initiate transfusion, while the massive hemorrhage protocol is activated from the blood bank.
  2. Patients transferred from another hospital
  3. Children <15 years (in most communities, patients aged 15-18 years are treated at adult trauma centers, and patients in this age group frequently suffer life-threatening injuries, and will therefore be included)
  4. Known prisoners, defined as individuals involuntarily confined or detained in a penal institution (including juvenile detention, involuntary psychiatric commitment, or court-ordered residential substance abuse treatment)
  5. Moribund patients expected to die within 1 hour
  6. Patients who required an ED thoracotomy or received more than 5 consecutive minutes of cardiopulmonary resuscitation (prior to receiving randomized blood products)
  7. Patients with known "do not resuscitate" orders prior to randomization
  8. Patients who refuse the administration of blood products
  9. Individuals with a research "opt out" bracelet.
  10. Greater than 20% total body surface area (TBSA) burns
  11. Suspected inhalation injury victims
  12. Patients who are obviously pregnant on clinical examination or known to be pregnant as provided by the subject or legally authorized representative

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Dvojnásobek

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Aktivní komparátor: LTOWB

Participants randomized to receive (Low Titer O Whole Blood [LTOWB])

Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously.

Aktivní komparátor: Components

Participants randomized to receive the component blood products.

Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
6-hour Mortality
Časové okno: First 6 hours after randomization

Participant vital status at 6-hours following randomization (randomization defined as product container is opened for administration to participant)

First 6 hours after randomization

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
24-hour Mortality
Časové okno: First 24 hours after randomization

Participant vital status at 24-hours following randomization

First 24 hours after randomization
Hospital/30-day Mortality
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Participant vital status at hospital discharge or 30-days post randomization (whichever the earlier)

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Incidence of Pre-specified Complications
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

The number of participants experiencing pre-specified complications. Pre-specified complications include: Acute kidney injury; Ventilator-associated pneumonia; Multiorgan failure; Transfusion-related hyperkalemia; Transfusion-related hypocalcemia; Transfusion associated circulatory overload; Acute respiratory distress syndrome; Symptomatic and asymptomatic deep vein thrombosis; Symptomatic and asymptomatic pulmonary embolism; Bleeding after hemostasis requiring intervention; Stroke; Myocardial infarction; Abdominal compartment syndrome; Transfusion-related allergic reactions; Febrile non-hemolytic transfusion reaction; Systemic inflammatory response syndrome; Sepsis; Alloimmunization in women of childbearing age

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Adjudicated Primary Cause of Death
Časové okno: 30-days post randomization

Primary cause of death as reviewed and determined by the study investigators (consensus)

30-days post randomization
Length of Stay (Hospital and Intensive Care Unit)
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Number of hours hospitalized (includes both hospital and intensive care unit time)

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Hospital-, Ventilator- and Intensive Care Unit-free days
Časové okno: 30-days post randomization

Number of days participant was alive and out of the hospital; number of days participant was not on a ventilator; and the number of days the participant was not in the intensive care unit.

30-days post randomization
Incidence of major surgical procedures
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

The proportion of participants undergoing major surgical procedures.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Time to hemostasis in those undergoing procedures with a hemostatic component
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete) following emergency department arrival.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Number and type of blood products used until hemostasis is achieved and from hemostasis to 24 hours after randomization
Časové okno: First 24 hours after randomization

The number of units and type of blood products (e.g. whole blood, packed red blood cells, platelets, plasma, etc.)

First 24 hours after randomization
Discharge destination
Časové okno: At hospital discharge or 30-days post randomization (whichever the earlier)

Discharge destination will be measured as a categorical variable. Categories will be tallied and compared between the two study arms. Example variables include: discharged to home, discharged to another primary care facility, discharged to hospice, etc.

At hospital discharge or 30-days post randomization (whichever the earlier)
Functional status
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Functional status will be measured by Extended Glasgow Outcome Scale (GOSE). The GOSE is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Patient's quality of life
Časové okno: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Quality of life will be measured by the Euroqol Group's EQ-5D quality of life measurement. The EQ-5D is a patient-reported questionnaire assessing health status in terms of five dimensions of health (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression). Lower EQ-5D scores are associated with better outcome.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Vyšetřovatelé

  • Vrchní vyšetřovatel: Jan Jansen, MBBS, PhD, University of Alabama at Birmingham

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Aktuální)

27. července 2023

Primární dokončení (Aktuální)

4. srpna 2026

Dokončení studie (Aktuální)

4. srpna 2026

Termíny zápisu do studia

První předloženo

8. listopadu 2022

První předloženo, které splnilo kritéria kontroly kvality

28. listopadu 2022

První zveřejněno (Aktuální)

6. prosince 2022

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

22. září 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

18. září 2026

Naposledy ověřeno

1. srpna 2026

Více informací

Termíny související s touto studií

Další identifikační čísla studie

  • IRB-300010517
  • 1UG3HL157401-01A1 (Grant/smlouva NIH USA)
  • 1U24HL157310-01A1 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ano

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit